538 results about "Thiazine" patented technology

The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components:

wherein X represents nitrogen atom or CH; R₁ represents CH_nF_3-n (wherein n is 1 or 2), hydroxy C₁–C₆ alkyl, NHR₆ [wherein R₆ represents hydrogen atom or COR (wherein R represents hydrogen atom, C₁–C₆ alkyl or C₁–C₆ alkoxy)]; R₂ represents morpholino (which may be substituted with one to four C₁–C₆ alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C₁–C₆ alkyl), oxazolidinyl (which may be substituted with one or two C₁–C₆ alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R₃ and R₄ each represent hydrogen atom or C₁–C₆ alkyl; and R₅ represents hydrogen atom, amino or hydroxyl.

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′-and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.

The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.

A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, alone or in combination with low levels of light or other drugs, to selectively inactivate or inhibit hepatitis infection, has been developed. Clinical trial results demonstrate efficacy in a human clinical trial for treatment of hepatitis C by oral administration of methylene blue immediate release formulation, in a dosage of 65 mg twice daily, over a period of at least 100 days. A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, along or in combination with low levels of light or other drugs, to prevent or decrease reactivation of viruses, is also described. The preferred class of patient is infected with, or has been exposed to, viruses such as Herpes simplex virus type 1 & 2, Varicella zoster virus, Epstein-Barr virus, Cytomegalovirus, and Herpes virus type 6 & 7, Adenovirus, and Human polyoma viruses, e.g. JC virus and BK virus. In one embodiment the thiazine dye is administered to a patient experiencing symptoms or disease caused by reactivation of a virus. In a preferred embodiment the thiazine dye is administered to a patient at risk for or experiencing symptoms or disease caused by reactivation of a virus, prior to or during immunosuppression or chemotherapy.

The invention relates to a method for production of an aqueous dispersion of polymer-encapsulated pigments, characterised in that (a) an aqueous pigment dispersion, containing at least one organic pigment (P), selected from the group of azo, isoindolinone, isoindoline, anthanthrone, thioindigo, thiazinindigo, triarylcarbonium, quinophthalone, anthraquinone, dioxazine, phthalocyanine, quinacridone, quinacridonquinone, indanthrone, perylene, perinone, pyranthrone, diketopyrrolopyrrole, isoviolanthrone and azomethine pigments, at least one detergent (T), and water is prepared, (b) a monomer miniemulsion, stabilised by a hydrophobic organic compound with a water solubility at 20 DEG C of at most 5x10<-5> g/l, is prepared from a polymerisable monomer (M) and at least one detergent (T) in water, (c) a monomer pigment emulsion is prepared, whereby the aqueous dispersion from (a) and the monomer miniemulsion from (b) are mixed and homogenised and (d) the pigment-containing monomer from (c) is polymerised in the presence of a polymerisation initiator and/or by heat, whereupon an encapsulation of the pigment with the polymer thus formed occurs.

The present invention provides the compounds inhibiting PDE 7 selectively, and therefore, enhances cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is imidazotirazinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl group, R2 is methyl group; R3 is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C1-C6 alkyl group; substituted or unsubstituted C2-C6 alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: —NR5R6, —C(O)R7, —SO2R7, —OR8, —NR8COR7, —NR8S02R7; A is CR4; and B is CH.

An object of the present invention is to provide a material for more easily and accurately detecting treatment status using gas exposure. The present invention relates to an ink composition for detecting an oxidizing gas, or the like, comprising at least one type of azo dye, methine dye, triarylmethane dye and thiazine dye.

This invention relates to compounds of formula I,

wherein R¹ to R³ are as defined herein, as well as pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and methods for using such compounds for the treatment or prevention of diabetes, particularly type 2 diabetes.

The present invention relates to methods and reagents for modifying the emission of light from labeled nucleic acids for the purpose of real time detection, analysis, and quantitation of nucleic acid sequences, e.g., using singly labeled probes. These methods and reagents exploit advantageous properties of thiazine dyes and diazine dyes. Furthermore, the use of these light emission modifiers in background reduction, nucleic acid duplex stabilization and other uses is also described. Related kits, reaction mixtures and integrated systems are described.

This invention relates to lubricating oil additives, and to lubricating oil compositions, their method of preparation, and use. More specifically, this invention relates to several novel lubricating oil additives and compositions which contain a tungsten compound and an antioxidant, namely aminic antioxidants such as a secondary diarylamine or an alkylated phenothiazine. The use of the tungsten compound with the secondary diarylamine and/or the alkylated phenothiazine provides improved oxidation and deposit control to lubricating oil compositions. The lubricating oil compositions of this invention are particularly useful as crankcase and transmission lubricants, gear oils and other high performance lubricant applications.

The invention relates to a medicinal oral preparation containing Valsartan and Hydrochlorothiazide, more specifically the dispersible tablets for enhancing the beneficial effects of Valsartan and Hydrochlorothiazide.

An active insecticide for preventing and eliminating the agricultural pests, such as thrips, aphis, aleyrodid, leafhopper, plant hopper, rice borer, etc, is proportionally prepared from pymetrozine and other active components chosen from pyriproxyfen, methylamino abamectin benzoate and buprofezin.

The invention discloses a thermal activation delayed fluorescence material based on a dibenzophenazine derivative as well as a preparation method and application of the thermal activation delayed fluorescence material, and belongs to the technical field of organic photoelectric materials and devices. The structural formula of the material is shown as a formula (I), in the formula (I), R1 is phenoxazinyl, phenothiazinyl or dimethyl acridinyl, R1' is phenoxazinyl, phenothiazinyl or dimethyl acridinyl, R1 '' is phenoxazinyl, phenothiazinyl or dimethyl acridinyl, and R2 is H, phenoxazinyl, phenothiazinyl or dimethyl acridinyl. The material provided by the invention has the advantages that the electron acceptor and the electron donor unit show a highly distorted rigid structure, 100% theoretical internal quantum efficiency can be realized, the fluorescence quantum yield is high, a guarantee is provided for a high-efficiency long-waveband OLED device, and the like. And a polysubstitution mode is adopted, so that red shift of molecular emission wavelength is facilitated, long-waveband luminescence is realized, and a guarantee is provided for an efficient long-waveband OLED device.

Inhibition of RNA function, and treatment or control of diseases or conditions, e.g. infectious diseases such as viruses and viral infections (including HIV) and microbial infections, by the contacting of the RNA with a compound having a central or core structure comprising three fused rings containing from 12 to 15 ring atoms, the central ring including at least one heteroatom selected from nitrogen, oxygen and sulfur, the atoms of the three-ring core structure being optionally substituted with substituents such as halogens, cyano, and/or various substituted or unsubstituted aliphatic and/or heteroaliphatic moieties, or contacting the RNA with yohimbine, usnic acid or N-{4-[2,5-Dioxo-1-(4-trifluoromethoxy-phenyl)-pyrrolidin-3-yl]-phenyl}-2,2,2-trifluoro-acetamide. Preferred compounds are various phenothiazines, including both known and novel compounds.

This invention relates to an anti-infective compound, more specifically, 6-fluoro-1-methyl-4-oxo-7-(1-piperazine)-4H-[1, 3] thiazine [3, 2-a] quinoline-3-carboxylic mesylate (compound I), its preparation method and its application. Compound I is prepared by reaction of 6-fluoro-1-methyl-4-oxo-7-(1-piperazine)-4H-[1,3]thiazine[3,2-a]quinoline-3-carboxylic acid and methyl sulfonic acid. Compound I can be used as effective component and mixed with normal pharmaceutical carrier to manufacture anti-infective drug composition, which can be tablets, capsules, granules, injection, eye preparations, ear preparations, gynecological preparations, and external use preparations. Compound I has stable properties, and can be easily dissolved in water, thus can be easily manufactured into various preparations used in clinical treatment. The method has such advantages as simple and reasonable process.

A conjugated polymer having a phenoxazine structure and a phenothiazine structure as subsituents.

The invention discloses a preparation method and medical application of 4-tert-butyl-6-phenyl-2-amino-6H-1,3-thiazine salt. The preparation method of the 4-tert-butyl-6-phenyl-2-amino-6H-1,3-thiazine salt comprises the steps of: stirring 0.010 mol of 1-phenyl-4,4-dimethyl pentene-3-ketone, 0.012 mol of thiourea and 0.011 mol of acid in an organic solvent at a temperature of between 30 and 80 DEG C, performing TLC detection on reaction process, completing reaction, filtering, washing and drying the obtained product and obtaining the 4-tert-butyl-6-phenyl-2-amino-6H-1,3-thiazine salt (I). The 4-tert-butyl-6-phenyl-2-amino-6H-1,3-thiazine salt (I) can be medically used for preparing influenza virus neuraminidase inhibitors. In a formula, HX is hydrochloric acid, phosphoric acid, hydrobromic acid, sulphuric acid, trifluoroacetic acid or methanesulfonic acid, and Y is Cl, Br, CH3, Et, CF3, OCH3 or OEt.

The invention discloses an insecticidal composition containing sulfoxaflor, comprising A and B components, wherein the active component A is selected from sulfoxaflor and the active component B is selected from any one of the following insecticides: pymetrozine, imidacloprid, acetamiprid, nitenpyram, thiamethoxam, buprofezin, thiacloprid, clothianidin and dinotefuran; and the weight percentage of the active components A to B is: (1-50%): (1-50%). The composition can be used for preventing and treating many insects, has obvious synergy, expands the insecticidal range and has relatively high activity on sucking insects such as plant hopper, aphid, Empoasca pirisuga Matsumura and aleyrodid, and Lepidoptera pests such as plutella xylostella and spodoptera exigua. Furthermore, the composition reduces the usage of the farm chemical and residue of the farm chemical on the crops, alleviates the environment pollution, and has safety on both human and poultry, good environment compatibility; and the insects are difficult to generate drug resistance.

The invention relates to a phenothiazine compound and a preparation method thereof. The invention further relates the application of the phenothiazine compound in anti-cancer drug preparation and anti-cancer drugs using the compound as the effective component. The phenothiazine compound has the advantages that the compound with broad-spectrum anti-cancer effect is obtained by modifying phenothiazine ternary interlink parent nucleuses, synthesizing method is simple, and high yield is achieved; the phenothiazine compound has certain restraining effect on human breast cancer cells line MCF-7 and human hepatoma cell line Hep-G2, and a new thought is provided to new drugs satisfying clinic requirements.